Onco-Targets – Making loss of SFRP tumour suppressor function druggable
The invention discloses molecules, which are activated,
when function of Secreted Fizzled Related Protein 1 (SFRP1) is lost. SFRP1 is known to have tumour suppressor function and its loss is associated to tumour progression and poor survival. Access to the signalling pathways regulated by SFRP1 leads to novel targets for cancer therapy and diagnosis. Such druggable targets open the route to screening of small molecules and design of monoclonal antibodies, thereby enabling the development of innovative oncological treatments as well as new diagnostic markers.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Why getting in touch with our ‘gerbil brain’ could help machines listen better
Macquarie University researchers have debunked a 75-year-old theory about how humans determine where sounds are coming from, and it could unlock the secret to creating a next generation of more…
Attosecond core-level spectroscopy reveals real-time molecular dynamics
Chemical reactions are complex mechanisms. Many different dynamical processes are involved, affecting both the electrons and the nucleus of the present atoms. Very often the strongly coupled electron and nuclear…
Free-forming organelles help plants adapt to climate change
Scientists uncover how plants “see” shades of light, temperature. Plants’ ability to sense light and temperature, and their ability to adapt to climate change, hinges on free-forming structures in their…
